Osimertinib is manufactured by AstraZeneca [1].
Who else makes or is developing Osimertinib?
Currently, AstraZeneca is the primary manufacturer of osimertinib. However, as patents approach expiration, other companies may develop generic versions. Information on specific companies involved in the development of generic osimertinib can be found through resources like DrugPatentWatch.com [2].
When does the patent for Osimertinib expire?
The patent landscape for osimertinib is complex, with various patents covering different aspects of the drug, including its formulation and method of use. For detailed information on specific patent expiry dates and their implications for market exclusivity, DrugPatentWatch.com is a valuable resource [2].
How effective is Osimertinib for EGFR-mutated lung cancer?
Osimertinib is a targeted therapy that inhibits specific mutations of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) [3]. Clinical trials have demonstrated its efficacy in patients with EGFR-mutated NSCLC, particularly those with the T790M resistance mutation [4].
What are the side effects of Osimertinib?
Common side effects reported for osimertinib include diarrhea, rash, dry skin, and nausea [5]. More serious side effects can also occur, and patients should discuss any concerns with their healthcare provider.
How does Osimertinib compare to other EGFR inhibitors?
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI). It is designed to be effective against common EGFR mutations, including the T790M resistance mutation that can develop after treatment with earlier-generation EGFR TKIs [4]. This can make it a treatment option for patients whose cancer has progressed on other therapies [4].